PMV PHARMACEUTICALS INC (PMVP) Stock Analyst Earnings Estimates
NASDAQ:PMVP - Nasdaq - US69353Y1038 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 376.51% | N/A 96.04% | N/A 121.30% | N/A 27.74% | N/A 20.55% | ||||||||
| EBITDA YoY % growth | -18.55M | -26.25M -41.51% | -34.62M -31.89% | -57.98M -67.48% | -76.72M -32.32% | -78.875M -2.81% | -84.304M -6.88% | N/A -16.53% | N/A -25.68% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -18.89M | -26.64M -41.03% | -34.94M -31.16% | -58.29M -66.83% | -77.04M -32.17% | -80.132M -4.01% | -85.448M -6.63% | N/A -8.15% | N/A -11.83% | N/A 1.67% | N/A 37.87% | N/A 59.63% | N/A 335.75% | N/A 51.10% | N/A 43.82% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.28 39.01% | -1.62 -26.56% | -1.45 10.49% | -1.14 21.38% | N/A -38.09% | N/A -14.04% | N/A 11.08% | N/A 27.16% | N/A 60.53% | N/A 626.67% | N/A 44.30% | N/A 29.53% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.41 -10.27% | -0.43 5.55% | -0.45 -32.00% | -0.48 -18.17% | -0.49 -21.25% | -0.50 -17.60% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.844M -8.93% | -24.158M 4.01% | -24.353M -12.93% | -25.628M -12.36% | -26.393M -10.69% | -26.826M -11.04% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.41 -1,950.00% | -0.39 | -0.02 | -4.86% |
| Q1 2025 Q2Q % growth | -0.34 -13.33% | -0.38 | 0.04 | 10.97% |
| Q4 2024 Q2Q % growth | -0.45 -45.16% | -0.39 | -0.06 | -15.92% |
| Q3 2024 Q2Q % growth | -0.37 -8.82% | -0.36 | -0.01 | -3.35% |
| Q2 2024 Q2Q % growth | -0.02 94.74% | -0.36 | 0.34 | 94.40% |
| Q1 2024 Q2Q % growth | -0.30 28.57% | -0.37 | 0.07 | 18.41% |
| Q4 2023 Q2Q % growth | -0.31 27.91% | -0.39 | 0.08 | 21.26% |
| Q3 2023 Q2Q % growth | -0.34 15.00% | -0.45 | 0.11 | 25.26% |
| Q2 2023 Q2Q % growth | -0.38 | -0.48 | 0.10 | 21.57% |
| Q1 2023 Q2Q % growth | -0.42 -2.44% | -0.47 | 0.05 | 10.16% |
| Q4 2022 Q2Q % growth | -0.43 -7.50% | -0.45 | 0.02 | 3.82% |
| Q3 2022 Q2Q % growth | -0.40 -21.21% | -0.43 | 0.03 | 7.36% |
| Q2 2022 Q2Q % growth | -0.38 -31.03% | -0.42 | 0.04 | 8.76% |
| Q1 2022 Q2Q % growth | -0.41 -57.69% | -0.41 | 0.00 | 0.34% |
| Q4 2021 Q2Q % growth | -0.40 31.20% | -0.35 | -0.05 | -13.12% |
| Q3 2021 Q2Q % growth | -0.33 77.40% | -0.31 | -0.02 | -7.25% |
| Q2 2021 Q2Q % growth | -0.29 | -0.29 | 0.00 | -0.82% |
| Q1 2021 Q2Q % growth | -0.26 | -0.24 | -0.02 | -6.21% |
| Q3 2020 Q2Q % growth | -1.46 | -0.35 | -1.11 | -314.89% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 4.02% | 0% | -0.18% |
| Revenue | N/A | N/A | N/A | N/A |